Cardioprotective Strategies in Isoproterenol-Induced Myocardial Injury

Isoproterenol, a synthetic β-adrenergic agonist, is widely used to model acute myocardial injury through induction of oxidative stress, inflammation and cardiomyocyte apoptosis. Research efforts have focused on interventions that bolster endogenous antioxidant defences, inhibit pro-inflammatory signalling and enhance cell survival pathways. Cardioprotective strategies range from natural phytoconstituents and nutraceuticals to small-molecule drugs, all aiming to attenuate lipid peroxidation, preserve membrane integrity and reduce infarct size. Central to many approaches is the activation of cytoprotective transcription factors and kinase cascades, such as Nrf2/HO-1 and PI3K/Akt, alongside suppression of NF-κB/TNF-α-mediated inflammation. These findings underscore the translational potential of multi-targeted therapies to mitigate adrenergic-stress-induced cardiac damage and inform development of adjunct treatments for ischaemic heart disease.

Research from Nature Portfolio

Recent investigations have demonstrated that a blend of traditional phytoconstituents, notably paeonol and danshensu, significantly reduces isoproterenol-triggered myocardial damage by bolstering antioxidant defences, suppressing lipid peroxidation and inhibiting apoptotic cascades via activation of Nrf2/HO-1 and PI3K/Akt pathways. Complementing this, studies on an iridoid glycoside have revealed maintenance of normal electrocardiographic patterns, preservation of cardiac ultrastructure and stabilisation of energy metabolism proteins, thereby attenuating infarct size. Additionally, co-administration of syringic acid and resveratrol has been shown to dampen NF-κB and TNF-α signalling, restore endogenous enzyme markers and improve lipid homeostasis, collectively mitigating inflammatory injury.

Cardioprotective Strategies in Isoproterenol-Induced Myocardial Injury publication trend

The graph below shows the total number of articles in cardioprotective strategies in isoproterenol-induced myocardial injury across all publications each year (not limited to Nature Index journals).

Technical terms

Isoproterenol: A synthetic catecholamine used experimentally to induce myocardial stress and infarction by overstimulating β-adrenergic receptors.

Oxidative stress: A pathological state arising from an imbalance between reactive oxygen species generation and antioxidant defences, leading to molecular damage.

Apoptosis: Programmed cell death characterised by specific biochemical and morphological changes, playing a role in cardiomyocyte loss during injury.

Nrf2/HO-1 pathway: A cytoprotective signalling axis in which nuclear factor erythroid 2-related factor 2 upregulates heme oxygenase-1 to coordinate antioxidant gene expression.

PI3K/Akt pathway: An intracellular kinase cascade that promotes cell survival and growth by phosphorylating downstream targets.

NF-κB: A transcription factor complex that regulates genes involved in inflammation, immunity and cell survival.

Tumour necrosis factor-α (TNF-α): A pro-inflammatory cytokine implicated in myocardial inflammation and apoptosis following ischaemic or adrenergic stress.

References

1. Paeonol and danshensu combination attenuates apoptosis in myocardial infarcted rats by inhibiting oxidative stress: Roles of Nrf2/HO-1 and PI3K/Akt pathway. Scientific Reports (2016).
2. Preventive effect of Agnucastoside C against Isoproterenol-induced myocardial injury. Scientific Reports (2017).
3. Combined cardio-protective ability of syringic acid and resveratrol against isoproterenol induced cardio-toxicity in rats via attenuating NF-kB and TNF-α pathways. Scientific Reports (2020).
4. Dapsone Ameliorates Isoproterenol-Induced Myocardial Infarction via Nrf2/ HO-1; TLR4/ TNF-α Signaling Pathways and the Suppression of Oxidative Stress, Inflammation, and Apoptosis in Rats. Frontiers in Pharmacology (2021).
5. L-carnitine protects cardiac damage by reducing oxidative stress and inflammatory response via inhibition of tumor necrosis factor-alpha and interleukin-1beta against isoproterenol-induced myocardial infarction. Biomedicine & Pharmacotherapy (2021).